Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9